首页 > 最新文献

Current Drug Therapy最新文献

英文 中文
Organoids Research for Colorectal Cancer: Promising Approach for Precision Medicine, their Applications and Future Perspectives 结直肠癌类器官研究:精准医学的前景、应用与展望
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-10-02 DOI: 10.2174/0115748855266739230919110125
Sonia Singh, Ashima Ahuja, Raghavan Ramankutty, sarada Ramaswamy
Background: Organoids are three-dimensional (3D) constructs designed to emulate the complexity and functionality of organs in the body. Organoids have recently been used as powerful instruments for modeling and investigating several diseases, including colorectal cancer. Colorectal cancer is caused by altering colonic epithelial cells, which produce adenomas and carcinomas. Objective: The objective of present study was to investigate impact of organoids on colorectal cancer and their therapeutic outcome in cancer research. Organoids can be grown from stem cells in vitro, which closely resemble the structure and function of the organ they are derived from. They have been used in a variety of research applications, including disease modeling, drug screening, and personalized medicine. Organoids have allowed researchers to understand better the mechanisms underlying colorectal cancer initiation, progression, and resistance to therapy. Methods: The literature review was surveyed, and keywords related to cancer management, organoids, modelling, personized medicine, 3D structures were screened for colorectal cancer management were screened in SCI-hub, SCOPUS, WOS, and ABC Journals. Results: The findings of studies suggested that organoids derived from patient tumors can recapitulate the histopathology and genetic alterations of the original tumor, making them a valuable tool for personalized medicine. Conclusion: Organoids have been used to develop high-throughput drug screening assays and investigate the tumor microenvironment's contribution to colorectal cancer progression. In this review, we summarize recent advances in the use of organoids to study colorectal cancer and discuss their potential applications in the clinic.
背景:类器官是三维(3D)结构,旨在模拟体内器官的复杂性和功能。类器官最近被用作建模和研究包括结直肠癌在内的几种疾病的有力工具。结直肠癌是由改变结肠上皮细胞引起的,结肠上皮细胞产生腺瘤和癌。目的:探讨肿瘤研究中类器官对结直肠癌的影响及其治疗效果。类器官可以在体外从干细胞中培养出来,这些干细胞的结构和功能与来源于它们的器官非常相似。它们已被用于各种研究应用,包括疾病建模、药物筛选和个性化医疗。类器官使研究人员能够更好地了解结肠直肠癌的发生、发展和耐药机制。方法:通过文献查阅,在SCI-hub、SCOPUS、WOS、ABC期刊中筛选大肠癌管理相关的肿瘤管理、类器官、建模、个性化医学、3D结构等关键词。结果:研究结果表明,来自患者肿瘤的类器官可以再现原始肿瘤的组织病理学和遗传改变,使其成为个性化医疗的宝贵工具。结论:类器官已被用于开发高通量药物筛选试验和研究肿瘤微环境对结直肠癌进展的贡献。在这篇综述中,我们总结了近年来使用类器官研究结直肠癌的进展,并讨论了它们在临床中的潜在应用。
{"title":"Organoids Research for Colorectal Cancer: Promising Approach for Precision Medicine, their Applications and Future Perspectives","authors":"Sonia Singh, Ashima Ahuja, Raghavan Ramankutty, sarada Ramaswamy","doi":"10.2174/0115748855266739230919110125","DOIUrl":"https://doi.org/10.2174/0115748855266739230919110125","url":null,"abstract":"Background: Organoids are three-dimensional (3D) constructs designed to emulate the complexity and functionality of organs in the body. Organoids have recently been used as powerful instruments for modeling and investigating several diseases, including colorectal cancer. Colorectal cancer is caused by altering colonic epithelial cells, which produce adenomas and carcinomas. Objective: The objective of present study was to investigate impact of organoids on colorectal cancer and their therapeutic outcome in cancer research. Organoids can be grown from stem cells in vitro, which closely resemble the structure and function of the organ they are derived from. They have been used in a variety of research applications, including disease modeling, drug screening, and personalized medicine. Organoids have allowed researchers to understand better the mechanisms underlying colorectal cancer initiation, progression, and resistance to therapy. Methods: The literature review was surveyed, and keywords related to cancer management, organoids, modelling, personized medicine, 3D structures were screened for colorectal cancer management were screened in SCI-hub, SCOPUS, WOS, and ABC Journals. Results: The findings of studies suggested that organoids derived from patient tumors can recapitulate the histopathology and genetic alterations of the original tumor, making them a valuable tool for personalized medicine. Conclusion: Organoids have been used to develop high-throughput drug screening assays and investigate the tumor microenvironment's contribution to colorectal cancer progression. In this review, we summarize recent advances in the use of organoids to study colorectal cancer and discuss their potential applications in the clinic.","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135901218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acknowledgement to Reviewers 审稿人致谢
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-10-01 DOI: 10.2174/157488551805230525105218
{"title":"Acknowledgement to Reviewers","authors":"","doi":"10.2174/157488551805230525105218","DOIUrl":"https://doi.org/10.2174/157488551805230525105218","url":null,"abstract":"","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136139312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the Protective Effects of Vitamins E and D on Oxidative Stress and Inflammation Caused by Tamoxifen in the Renal Tissue of Female Wistar Rats 维生素E和D对雌性Wistar大鼠肾组织氧化应激和他莫昔芬所致炎症的保护作用
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-09-18 DOI: 10.2174/1574885519666230918091035
Mohammed zardashat khalid, Sina Mohagheghi, Roghayyeh Abbasali Pourkabir, Mahdi Bahmani, Alireza Nourian, Gholamreza Shafiee
Background: Tamoxifen is an effective drug for breast cancer treatment and its side effects are the production of reactive oxygen species and kidney damage. As antioxidants, vitamins E and D may help decrease kidney dysfunction. Objective: In the present study, the protective effects of vitamins E and D on renal toxicity caused by tamoxifen in female Wistar rats were investigated. Materials and methods: Twenty-five adult female rats weighing 180-200 were randomly divided into five groups with 5 rats. Group C, T, TE, TD, and TED were treated with olive oil, tamoxifen, tamoxifen + vitamin E, tamoxifen +vitamin D, and tamoxifen + both vitamins for four weeks. ELISA Kits measured the oxidant and antioxidant tests and TNF-α in kidney tissue. The spectrophotometric method measured urea, uric acid, and creatinine in serum and urine. Results: Tamoxifen significantly decreased the weight of rats, GPx, CAT, SOD levels and increased TNF-α, urinary creatinine level and, serum uric acid, urea levels (P<0.05). But, treatment with vitamin D and simultaneous administration of vitamins led to a significant decrease in the level of (TNF-α) compared to the tamoxifen group (p<0.01). Also, the histopathology results showed that the simultaneous administration of vitamins has significantly resolved the damage caused by the use of tamoxifen. Conclusion: The present study's findings showed that using vitamins E and D prevents kidney damage through antioxidant and anti-inflammatory effects. In addition, using vitamins E and D probably showed stronger synergistic effects against kidney damage.
背景:他莫昔芬是治疗乳腺癌的有效药物,其副作用是产生活性氧和损害肾脏。作为抗氧化剂,维生素E和D可能有助于减少肾功能障碍。目的:研究维生素E和D对雌性Wistar大鼠他莫昔芬所致肾毒性的保护作用。材料与方法:体重180 ~ 200的成年雌性大鼠25只,随机分为5组,每组5只。C组、T组、TE组、TD组和TED组分别用橄榄油、他莫昔芬、他莫昔芬+维生素E、他莫昔芬+维生素D、他莫昔芬+两种维生素治疗4周。ELISA试剂盒检测肾组织氧化、抗氧化指标及TNF-α。分光光度法测定血清和尿液中的尿素、尿酸和肌酐。结果:他莫昔芬显著降低大鼠体重、GPx、CAT、SOD水平,升高TNF-α、尿肌酐水平和血清尿酸、尿素水平(P<0.05)。但是,与他莫昔芬组相比,维生素D治疗和同时给予维生素可导致TNF-α水平显著降低(p<0.01)。同时,组织病理学结果显示,同时给予维生素可以显著解决使用他莫昔芬造成的损伤。结论:本研究结果表明,使用维生素E和D通过抗氧化和抗炎作用防止肾脏损伤。此外,服用维生素E和D可能对肾脏损害有更强的协同作用。
{"title":"Evaluation of the Protective Effects of Vitamins E and D on Oxidative Stress and Inflammation Caused by Tamoxifen in the Renal Tissue of Female Wistar Rats","authors":"Mohammed zardashat khalid, Sina Mohagheghi, Roghayyeh Abbasali Pourkabir, Mahdi Bahmani, Alireza Nourian, Gholamreza Shafiee","doi":"10.2174/1574885519666230918091035","DOIUrl":"https://doi.org/10.2174/1574885519666230918091035","url":null,"abstract":"Background: Tamoxifen is an effective drug for breast cancer treatment and its side effects are the production of reactive oxygen species and kidney damage. As antioxidants, vitamins E and D may help decrease kidney dysfunction. Objective: In the present study, the protective effects of vitamins E and D on renal toxicity caused by tamoxifen in female Wistar rats were investigated. Materials and methods: Twenty-five adult female rats weighing 180-200 were randomly divided into five groups with 5 rats. Group C, T, TE, TD, and TED were treated with olive oil, tamoxifen, tamoxifen + vitamin E, tamoxifen +vitamin D, and tamoxifen + both vitamins for four weeks. ELISA Kits measured the oxidant and antioxidant tests and TNF-α in kidney tissue. The spectrophotometric method measured urea, uric acid, and creatinine in serum and urine. Results: Tamoxifen significantly decreased the weight of rats, GPx, CAT, SOD levels and increased TNF-α, urinary creatinine level and, serum uric acid, urea levels (P<0.05). But, treatment with vitamin D and simultaneous administration of vitamins led to a significant decrease in the level of (TNF-α) compared to the tamoxifen group (p<0.01). Also, the histopathology results showed that the simultaneous administration of vitamins has significantly resolved the damage caused by the use of tamoxifen. Conclusion: The present study's findings showed that using vitamins E and D prevents kidney damage through antioxidant and anti-inflammatory effects. In addition, using vitamins E and D probably showed stronger synergistic effects against kidney damage.","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135207796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A sustainable approach towards prevention and treatment of hepatic and other disorders associated with alcohol consumption 预防和治疗与饮酒有关的肝脏和其他疾病的可持续方法
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-09-15 DOI: 10.2174/1574885519666230915103206
Zulfa Nooreen, Ankita Shukla, Anuja Shukla, Priyanka Verma
Background: Alcohol has been used for centuries in many different civilizations. It is a psychoactive stimulant with addictive properties. Alcohol misuse has significant negative social, economic, and health effects. Abusing alcohol can cause harm to oneself as well as to relatives, coworkers, close companions, and total strangers. Alcohol usage contributes to more than 200 diseases, accidents, and other health problems. Drinking alcohol is associated with a higher chance of developing significant non-communicable illnesses such liver cirrhosis, a number of cancers, cardiovascular diseases, as well as behavioral and mental disorders like alcoholism. Objective: Abuse of alcohol does not occur suddenly. People becoming addicted to various alcoholic beverages is a problem that results from months and years of irresponsible drinking. The process of recovering from the issue in turn includes targeted, particular methods for raising awareness of the negative effects of alcohol usage. Conclusion: Due to the heightened risks for one's bodily and mental health along with the social issues it generates, alcohol consumption results in these costs. We discuss the three areas of the epidemiology of alcohol's impact on health and diseases, the public health approach for treating problems related to alcohol use,and advancements in alcohol science.
背景:在许多不同的文明中,酒已经被使用了几个世纪。它是一种具有成瘾特性的精神兴奋剂。酒精滥用对社会、经济和健康都有显著的负面影响。酗酒不仅会对自己造成伤害,也会对亲戚、同事、亲密伴侣和完全陌生的人造成伤害。饮酒会导致200多种疾病、事故和其他健康问题。饮酒与患肝硬化、多种癌症、心血管疾病以及酗酒等行为和精神障碍等严重非传染性疾病的几率较高有关。目的:酒精滥用不是突然发生的。人们对各种酒精饮料上瘾是数月或数年不负责任饮酒的结果。从这一问题中恢复过来的过程反过来包括有针对性的、特别的方法,以提高人们对饮酒负面影响的认识。结论:由于一个人的身体和心理健康的风险增加,以及它产生的社会问题,酒精消费导致了这些成本。我们讨论了酒精对健康和疾病影响的流行病学、治疗与酒精使用有关的问题的公共卫生方法以及酒精科学的进展这三个领域。
{"title":"A sustainable approach towards prevention and treatment of hepatic and other disorders associated with alcohol consumption","authors":"Zulfa Nooreen, Ankita Shukla, Anuja Shukla, Priyanka Verma","doi":"10.2174/1574885519666230915103206","DOIUrl":"https://doi.org/10.2174/1574885519666230915103206","url":null,"abstract":"Background: Alcohol has been used for centuries in many different civilizations. It is a psychoactive stimulant with addictive properties. Alcohol misuse has significant negative social, economic, and health effects. Abusing alcohol can cause harm to oneself as well as to relatives, coworkers, close companions, and total strangers. Alcohol usage contributes to more than 200 diseases, accidents, and other health problems. Drinking alcohol is associated with a higher chance of developing significant non-communicable illnesses such liver cirrhosis, a number of cancers, cardiovascular diseases, as well as behavioral and mental disorders like alcoholism. Objective: Abuse of alcohol does not occur suddenly. People becoming addicted to various alcoholic beverages is a problem that results from months and years of irresponsible drinking. The process of recovering from the issue in turn includes targeted, particular methods for raising awareness of the negative effects of alcohol usage. Conclusion: Due to the heightened risks for one's bodily and mental health along with the social issues it generates, alcohol consumption results in these costs. We discuss the three areas of the epidemiology of alcohol's impact on health and diseases, the public health approach for treating problems related to alcohol use,and advancements in alcohol science.","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135485363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lysosomal storage diseases: Natural products inducing autophagy 溶酶体贮积病:诱导自噬的天然产物
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-09-15 DOI: 10.2174/1574885519666230915103100
Chandani Chandrana, Tahib Habshi, Arun Soni, Sanjeev Acharya
Background: The link between autophagy and lysosomal function has been well-recognised in recent dec-ades; defective autophagy and lysosomal function lead to various disorders, notably Lysoso-mal Storage Disorders (LSDs). The malfunction of multiple mechanistic pathways influences the contribution of LSDs. Different ways are employed in such situations, but one novel ap-proach could resolve the problem by inducing the autophagic pathway, which aids in main-taining proper autophagy and lysosomal degradation function. Method: Autophagic Inducer functions on the activation of Transcriptional factor EB (TFEB) and its mechanism; mTOR Complex Inhibition dependently or independently may repair the mal-function of the entire mechanism. Finding a potential autophagic inducer is still a work in progress, but targeting TFEB and mTOR could redefine LSD treatment. The development of experimentally available TFEB modulators could enhance autophagic flux promote lysosomal function and increase lysosomal biogenesis and can be a promising technique for treating ill-nesses caused by ALP dysfunction, such as lysosomal storage disorder. Result: MTORC1 suppression causes TFEB to be transported to the nucleus and transcription of mul-tiple genes involved in the formation of autophagosomes and lysosomes, indicating that MTORC1 has positive effects in treating lysosomal storage diseases such as Pompe disease, Batton disease, Fabry disease, etc. thus modulating autophagy attenuates the above condi-tion. Conclusion: This review comprises autophagy and lysosome association, and their malfunction leads to various lysosomal diseases. Several natural products are also discussed, which can be possible treatment options.
背景:近几十年来,自噬和溶酶体功能之间的联系已经得到了很好的认识;有缺陷的自噬和溶酶体功能导致各种疾病,特别是溶酶mal Storage disorders (lsd)。多种机制通路的故障影响lsd的作用。在这种情况下采用了不同的方法,但一种新的方法可以通过诱导自噬途径来解决问题,这有助于维持适当的自噬和溶酶体降解功能。方法:自噬诱导剂对转录因子EB (TFEB)的激活作用及其机制;mTOR复合物抑制可依赖或独立地修复整个机制的功能缺陷。寻找潜在的自噬诱导剂仍在进行中,但靶向TFEB和mTOR可能会重新定义LSD治疗。实验中发现的TFEB调节剂可以增强自噬通量,促进溶酶体功能,增加溶酶体的生物发生,是治疗溶酶体贮积症等由ALP功能障碍引起的疾病的一种很有前景的技术。结果:抑制MTORC1可使TFEB转运至细胞核,参与自噬体和溶酶体形成的多个基因转录,说明MTORC1对Pompe病、baton病、Fabry病等溶酶体贮积性疾病有积极作用,调节自噬可减轻上述情况。结论:本文综述了细胞自噬和溶酶体的结合,它们的功能障碍导致各种溶酶体疾病。还讨论了几种可能作为治疗选择的天然产品。
{"title":"Lysosomal storage diseases: Natural products inducing autophagy","authors":"Chandani Chandrana, Tahib Habshi, Arun Soni, Sanjeev Acharya","doi":"10.2174/1574885519666230915103100","DOIUrl":"https://doi.org/10.2174/1574885519666230915103100","url":null,"abstract":"Background: The link between autophagy and lysosomal function has been well-recognised in recent dec-ades; defective autophagy and lysosomal function lead to various disorders, notably Lysoso-mal Storage Disorders (LSDs). The malfunction of multiple mechanistic pathways influences the contribution of LSDs. Different ways are employed in such situations, but one novel ap-proach could resolve the problem by inducing the autophagic pathway, which aids in main-taining proper autophagy and lysosomal degradation function. Method: Autophagic Inducer functions on the activation of Transcriptional factor EB (TFEB) and its mechanism; mTOR Complex Inhibition dependently or independently may repair the mal-function of the entire mechanism. Finding a potential autophagic inducer is still a work in progress, but targeting TFEB and mTOR could redefine LSD treatment. The development of experimentally available TFEB modulators could enhance autophagic flux promote lysosomal function and increase lysosomal biogenesis and can be a promising technique for treating ill-nesses caused by ALP dysfunction, such as lysosomal storage disorder. Result: MTORC1 suppression causes TFEB to be transported to the nucleus and transcription of mul-tiple genes involved in the formation of autophagosomes and lysosomes, indicating that MTORC1 has positive effects in treating lysosomal storage diseases such as Pompe disease, Batton disease, Fabry disease, etc. thus modulating autophagy attenuates the above condi-tion. Conclusion: This review comprises autophagy and lysosome association, and their malfunction leads to various lysosomal diseases. Several natural products are also discussed, which can be possible treatment options.","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135485367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Auvelity: A New Era in Medicine - Unraveling the Multifaceted Benefits of Dextromethorphan/Bupropion Combination Auvelity:医学的新时代-揭示右美沙芬/安非他酮组合的多方面益处
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-09-13 DOI: 10.2174/1574885519666230913105725
Anchal Dhawan, Sunayna Choudhary, Sumeet Gupta, Abhishek Chander, Meenakshi Dhanawat
Background: Depression is a prevalent global illness, impacting 280 million people worldwide, and Major Depressive Disorder (MDD) is ranked as the third leading cause of disease burden globally. People previously diagnosed with depression are more likely to develop Alzheimer's disease (AD). The recent approval of Auvelity by the FDA has made a remarkable breakthrough in drug development, offering a multi-dimensional approach for managing multiple diseases. Objective: The main objective of this study is to investigate the role of Auvelity, a new drug, in treating MDD and its potential to manage agitation in individuals with Alzheimer's disease (AD). Methodology: Data on Auvelity was collected from various sources, including accessdata.fda.gov, PubMed, and Scopus, and compiled for analysis. Discussion: Auvelity is the first oral medication to demonstrate the rapid onset of action, with statistically significant antidepressant efficacy observed as early as one week compared to a placebo. It contains a combination of dextromethorphan (45 mg) and bupropion (105 mg). The drug's mechanism of action involves a combination of NMDA receptor blockade and agonism of the sigma-1 receptor, resulting in the antagonization of the glutamatergic neurotransmitter pathway. Due to the similarity in the mechanism of action with AD medications like Memantine, there is a hypothesis that Auvelity could effectively reduce symptoms of AD. Conclusion: The approval of Auvelity marks a significant advancement in depression treatment with its unique NMDA antagonist mechanism, rapid onset of action, and low-risk profile.
背景:抑郁症是一种普遍的全球性疾病,影响着全世界2.8亿人,重度抑郁症(MDD)被列为全球疾病负担的第三大原因。以前被诊断患有抑郁症的人更有可能患上阿尔茨海默病(AD)。最近FDA批准的Auvelity在药物开发方面取得了重大突破,为治疗多种疾病提供了多维方法。目的:本研究的主要目的是研究一种新药Auvelity在治疗重度抑郁症中的作用及其对阿尔茨海默病(AD)患者躁动的控制潜力。方法:Auvelity的数据从各种来源收集,包括accessdata.fda.gov、PubMed和Scopus,并进行编译以供分析。讨论:Auvelity是第一个证明起效迅速的口服药物,与安慰剂相比,早在一周就观察到统计学上显著的抗抑郁疗效。它含有右美沙芬(45毫克)和安非他酮(105毫克)的混合物。该药物的作用机制涉及NMDA受体阻断和sigma-1受体激动作用的结合,导致谷氨酸能神经递质通路的拮抗。由于与美金刚等AD药物的作用机制相似,有一种假设认为Auvelity可以有效地减轻AD的症状。结论:Auvelity凭借其独特的NMDA拮抗剂作用机制、起效快、低风险等特点,在抑郁症治疗领域取得了重大进展。
{"title":"Auvelity: A New Era in Medicine - Unraveling the Multifaceted Benefits of Dextromethorphan/Bupropion Combination","authors":"Anchal Dhawan, Sunayna Choudhary, Sumeet Gupta, Abhishek Chander, Meenakshi Dhanawat","doi":"10.2174/1574885519666230913105725","DOIUrl":"https://doi.org/10.2174/1574885519666230913105725","url":null,"abstract":"Background: Depression is a prevalent global illness, impacting 280 million people worldwide, and Major Depressive Disorder (MDD) is ranked as the third leading cause of disease burden globally. People previously diagnosed with depression are more likely to develop Alzheimer's disease (AD). The recent approval of Auvelity by the FDA has made a remarkable breakthrough in drug development, offering a multi-dimensional approach for managing multiple diseases. Objective: The main objective of this study is to investigate the role of Auvelity, a new drug, in treating MDD and its potential to manage agitation in individuals with Alzheimer's disease (AD). Methodology: Data on Auvelity was collected from various sources, including accessdata.fda.gov, PubMed, and Scopus, and compiled for analysis. Discussion: Auvelity is the first oral medication to demonstrate the rapid onset of action, with statistically significant antidepressant efficacy observed as early as one week compared to a placebo. It contains a combination of dextromethorphan (45 mg) and bupropion (105 mg). The drug's mechanism of action involves a combination of NMDA receptor blockade and agonism of the sigma-1 receptor, resulting in the antagonization of the glutamatergic neurotransmitter pathway. Due to the similarity in the mechanism of action with AD medications like Memantine, there is a hypothesis that Auvelity could effectively reduce symptoms of AD. Conclusion: The approval of Auvelity marks a significant advancement in depression treatment with its unique NMDA antagonist mechanism, rapid onset of action, and low-risk profile.","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135783972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current Challenges and Issues in Indian Regulations of Medical Devices 当前印度医疗器械法规的挑战和问题
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-09-12 DOI: 10.2174/1574885519666230912121853
Rohit Bhatia, Shubham Singh, Ananya Parashar, Arti R. Thakkar
Abstract: The study's objectives are to highlight the significance of medical devices, investigate the prospective expansion of the Indian market, look at the legislative changes made possible by MDR 2020, and deal with the ongoing issues with cost, quality, and adverse responses. The research aims to enhance the Indian medical devices sector by offering insightful observations and suggestions. This study intends to highlight the significance of medical devices, assess the prospective growth of the Indian industry, look at the regulatory changes brought about by MDR 2020, and address the ongoing issues with cost, quality, and adverse responses. The goal of the research is to help the Indian medical devices business grow by offering helpful insights and practical suggestions. The improvement of people's well-being and health depends heavily on medical technologies. The usage of medical devices is expected to rise as technology develops and illnesses spread. The Indian medical device industry is expected to grow to a market value of USD 50 billion by 2025, placing it fourth in Asia. The "Atma Nibbar Bharat" strategy, which emphasizes independence, is anticipated to support the expansion of India's medical device industry. Before the passage of the Medications and Cosmetics Act of 1940, there were no explicit regulations controlling medical devices, which resulted in their designation as medications. The Medical Device Regulation (MDR) was initially announced in 2017, nevertheless, and went into effect in January 2018. The Indian medical device sector was greatly impacted by the change of this guideline paper into MDR 2020. For testing and altering equipment that comes within the new criteria, the amended legislation offers a wider range of options. Despite these positive adjustments, problems still exist. Significant drawbacks include unregulated pricing, difficulties with quality control, and negative responses to medical equipment. This essay covers these topics in extensive detail and includes pertinent advice. It is stated which department is in control of handling these issues. To successfully address these issues, thorough examples, case studies, and solutions are given. In conclusion, this abstract emphasizes the significance of medical devices, the market's potential for growth in India, MDR 2020's legislative adjustments, as well as the ongoing difficulties related to cost, quality, and bad responses. The essay seeks to solve these problems by providing insightful analysis and suggestions.
摘要:本研究的目的是强调医疗器械的重要性,调查印度市场的预期扩张,观察MDR 2020可能带来的立法变化,并处理持续存在的成本、质量和不良反应问题。该研究旨在通过提供有见地的观察和建议来加强印度医疗器械行业。本研究旨在强调医疗器械的重要性,评估印度行业的前景增长,研究MDR 2020带来的监管变化,并解决持续存在的成本、质量和不良反应问题。这项研究的目的是通过提供有用的见解和实用的建议来帮助印度医疗器械业务的发展。人民福祉和健康的改善在很大程度上取决于医疗技术。随着技术的发展和疾病的传播,医疗设备的使用预计会增加。预计到2025年,印度医疗器械行业的市场价值将增长到500亿美元,在亚洲排名第四。强调独立的“Atma Nibbar Bharat”战略预计将支持印度医疗器械行业的扩张。在1940年药物和化妆品法案通过之前,没有明确的法规控制医疗器械,这导致它们被指定为药物。然而,医疗器械法规(MDR)最初于2017年宣布,并于2018年1月生效。印度医疗器械行业受到该指南文件更改为MDR 2020的巨大影响。对于测试和修改符合新标准的设备,修订后的法规提供了更广泛的选择。虽然进行了积极调整,但问题依然存在。重大缺陷包括不受监管的定价、质量控制方面的困难以及对医疗设备的负面反应。这篇文章涵盖了这些主题的广泛细节,并包括相关的建议。说明了哪个部门负责处理这些问题。为了成功地解决这些问题,本文给出了详尽的示例、案例研究和解决方案。总之,这篇摘要强调了医疗器械的重要性、印度市场的增长潜力、MDR 2020的立法调整,以及与成本、质量和不良反应相关的持续困难。本文试图通过提供深刻的分析和建议来解决这些问题。
{"title":"Current Challenges and Issues in Indian Regulations of Medical Devices","authors":"Rohit Bhatia, Shubham Singh, Ananya Parashar, Arti R. Thakkar","doi":"10.2174/1574885519666230912121853","DOIUrl":"https://doi.org/10.2174/1574885519666230912121853","url":null,"abstract":"Abstract: The study's objectives are to highlight the significance of medical devices, investigate the prospective expansion of the Indian market, look at the legislative changes made possible by MDR 2020, and deal with the ongoing issues with cost, quality, and adverse responses. The research aims to enhance the Indian medical devices sector by offering insightful observations and suggestions. This study intends to highlight the significance of medical devices, assess the prospective growth of the Indian industry, look at the regulatory changes brought about by MDR 2020, and address the ongoing issues with cost, quality, and adverse responses. The goal of the research is to help the Indian medical devices business grow by offering helpful insights and practical suggestions. The improvement of people's well-being and health depends heavily on medical technologies. The usage of medical devices is expected to rise as technology develops and illnesses spread. The Indian medical device industry is expected to grow to a market value of USD 50 billion by 2025, placing it fourth in Asia. The \"Atma Nibbar Bharat\" strategy, which emphasizes independence, is anticipated to support the expansion of India's medical device industry. Before the passage of the Medications and Cosmetics Act of 1940, there were no explicit regulations controlling medical devices, which resulted in their designation as medications. The Medical Device Regulation (MDR) was initially announced in 2017, nevertheless, and went into effect in January 2018. The Indian medical device sector was greatly impacted by the change of this guideline paper into MDR 2020. For testing and altering equipment that comes within the new criteria, the amended legislation offers a wider range of options. Despite these positive adjustments, problems still exist. Significant drawbacks include unregulated pricing, difficulties with quality control, and negative responses to medical equipment. This essay covers these topics in extensive detail and includes pertinent advice. It is stated which department is in control of handling these issues. To successfully address these issues, thorough examples, case studies, and solutions are given. In conclusion, this abstract emphasizes the significance of medical devices, the market's potential for growth in India, MDR 2020's legislative adjustments, as well as the ongoing difficulties related to cost, quality, and bad responses. The essay seeks to solve these problems by providing insightful analysis and suggestions.","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135885780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug targets, current and future therapeutics for the treatment of multi drug resistant tuberculosis with their clinical applications: A critical review 多药耐药结核病的药物靶点、当前和未来治疗方法及其临床应用综述
IF 0.6 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-08-30 DOI: 10.2174/1574885519666230830125139
Deepshikha Singh, Vikram Singh, S. Mandal, Karen Dsouza, B. R. P. Kumar, S. Dixit
Multi drug-resistant or extensive drug resistance Mycobacterium tuberculosis poses numerous challenges for health care workers and for public health authorities. Treating multidrug resistant or extensive drug resistance tuberculosis continues to be a difficult task, as a longer regimen is associated with a higher number of adverse drug events and economic burden and has a significant negative effect on health care resources. Many trials and observational studies were conducted. Few studies are underway to develop the universal regimen and improve the outcomes related to multi or extensive drug resistance tuberculosis with a shorter regimen duration. The current review will discuss which drug inhibits what target, their synthesis, genetic aspects, repurposed drugs, novel drugs, and extensive trials for the treatment of multi or extensive drug resistance tuberculosis.
多重耐药或广泛耐药结核分枝杆菌给卫生保健工作者和公共卫生当局带来了许多挑战。治疗耐多药或广泛耐药结核病仍然是一项艰巨的任务,因为较长的治疗方案与更多的药物不良事件和经济负担有关,并对卫生保健资源产生重大负面影响。进行了许多试验和观察性研究。目前正在进行的研究很少,以制定通用方案,并以较短的方案持续时间改善与多重或广泛耐药结核病有关的结果。本综述将讨论哪种药物抑制什么靶点、它们的合成、遗传方面、重新使用的药物、新药以及治疗多重或广泛耐药结核病的广泛试验。
{"title":"Drug targets, current and future therapeutics for the treatment of multi drug resistant tuberculosis with their clinical applications: A critical review","authors":"Deepshikha Singh, Vikram Singh, S. Mandal, Karen Dsouza, B. R. P. Kumar, S. Dixit","doi":"10.2174/1574885519666230830125139","DOIUrl":"https://doi.org/10.2174/1574885519666230830125139","url":null,"abstract":"\u0000\u0000Multi drug-resistant or extensive drug resistance Mycobacterium tuberculosis poses numerous challenges for health care workers and for public health authorities. Treating multidrug resistant or extensive drug resistance tuberculosis continues to be a difficult task, as a longer regimen is associated with a higher number of adverse drug events and economic burden and has a significant negative effect on health care resources. Many trials and observational studies were conducted. Few studies are underway to develop the universal regimen and improve the outcomes related to multi or extensive drug resistance tuberculosis with a shorter regimen duration. The current review will discuss which drug inhibits what target, their synthesis, genetic aspects, repurposed drugs, novel drugs, and extensive trials for the treatment of multi or extensive drug resistance tuberculosis.\u0000","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44355097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
3d Printing – A Revolution In Modern Healthcare: Recent Achievements & Challenges 3d打印-现代医疗保健的革命:最近的成就与挑战
IF 0.6 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-08-28 DOI: 10.2174/1574885519666230828152530
A. Thakkar, Anshul Chaudhary, Samiksha
The pharmaceutical industry grows every year keeping public health as a priority, protection, and economic development. The industry is mostly concentrated on the novel drug development process as well as new methods that can help improve the recovery rate of a condition and improve the quality of patient treatment. Pharmaceutical companies have recently experimented with producing medications using 3D printing to increase their quality and improve user health. Later, in 2015, the companies found success by producing the 3D-printed medication Spritam, which had already received US FDA approval. Over the past few years, the medical device industry has adapted to 3D printing technology and creative companies have used it to produce goods with distinctive content, appearance, and customizability. However, these distinctive capabilities of 3D printing have brought forth new legal difficulties and troubling issues with the regulatory agencies' acceptance of these devices. Customizability and distinctive construction procedures of medical devices printed via 3D printing techniques have difficulties in attaining quality assurance and regulatory criteria for manufacturing. Advancement in 3D printing technology has helped in the production of various innovative medical products along with new structures and constituents. The present review discusses distinctive regulatory problems faced by the USFDA as well as by other regulatory authorities in the case of approval of 3D printing products and measures required to develop regulations for the safety, quality, and effectiveness of 3D printing Devices.
制药行业每年都在增长,将公众健康作为优先事项、保护和经济发展。该行业主要集中在新药开发过程以及有助于提高病情恢复率和提高患者治疗质量的新方法上。制药公司最近尝试使用3D打印生产药物,以提高质量并改善用户健康。后来,在2015年,这些公司通过生产3D打印药物Spritam获得了成功,该药物已获得美国食品药品监督管理局的批准。在过去的几年里,医疗器械行业已经适应了3D打印技术,创意公司利用它生产出具有独特内容、外观和可定制性的产品。然而,3D打印的这些独特功能给监管机构接受这些设备带来了新的法律困难和令人不安的问题。通过3D打印技术打印的医疗设备的可定制性和独特的施工程序在实现制造的质量保证和监管标准方面存在困难。3D打印技术的进步有助于生产各种创新的医疗产品以及新的结构和成分。本综述讨论了美国食品药品监督管理局以及其他监管机构在批准3D打印产品时面临的独特监管问题,以及制定3D打印设备安全、质量和有效性法规所需的措施。
{"title":"3d Printing – A Revolution In Modern Healthcare: Recent Achievements & Challenges","authors":"A. Thakkar, Anshul Chaudhary, Samiksha","doi":"10.2174/1574885519666230828152530","DOIUrl":"https://doi.org/10.2174/1574885519666230828152530","url":null,"abstract":"\u0000\u0000The pharmaceutical industry grows every year keeping public health as a priority, protection, and economic development. The industry is mostly concentrated on the novel drug development process as well as new methods that can help improve the recovery rate of a condition and improve the quality of patient treatment. Pharmaceutical companies have recently experimented with producing medications using 3D printing to increase their quality and improve user health. Later, in 2015, the companies found success by producing the 3D-printed medication Spritam, which had already received US FDA approval. Over the past few years, the medical device industry has adapted to 3D printing technology and creative companies have used it to produce goods with distinctive content, appearance, and customizability. However, these distinctive capabilities of 3D printing have brought forth new legal difficulties and troubling issues with the regulatory agencies' acceptance of these devices. Customizability and distinctive construction procedures of medical devices printed via 3D printing techniques have difficulties in attaining quality assurance and regulatory criteria for manufacturing. Advancement in 3D printing technology has helped in the production of various innovative medical products along with new structures and constituents. The present review discusses distinctive regulatory problems faced by the USFDA as well as by other regulatory authorities in the case of approval of 3D printing products and measures required to develop regulations for the safety, quality, and effectiveness of 3D printing Devices.\u0000","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2023-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45907256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Severe and Prolonged Thrombocytopenia Following Heparin and Apixaban Use: A Case Report and Literature Review 肝素和阿哌沙班使用后严重和长期的血小板减少:1例报告和文献回顾
IF 0.6 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-08-25 DOI: 10.2174/1574885519666230825153414
Foroud Shahbazi, M. Salimi
Drug-induced thrombocytopenia can occur in hospitalized patients and complicate their antithrombotic treatment. Several medications can associate thrombocytopenia with immune and non-immune mechanisms. Thrombocytopenia can occur at any time from a few hours to months after a new medication initiation. In this study, we have described the case of a female patient with acute-on-chronic kidney injury following a non-steroidal anti-inflammatory agent use, who developed catheter-related thrombosis and was treated with heparin without any complication for 5 days. She was discharged after 5 days and prescribed to use apixaban 2.5 mg twice daily. However, she was readmitted after 24 hours with fatigue, petechiae, and severe thrombocytopenia (7000/mm3). The workup was negative for other reasons of thrombocytopenia. With a possible diagnosis of drug-related thrombocytopenia, apixaban was discontinued. Following the treatment with the intravenous immunoglobulin, her platelet counts increased and stabilized around 40-50,000/mm3. Anticoagulation was thus continued with adjusted doses of rivaroxaban (10-15 mg/day). 17 days after apixaban discontinuation and treatment with prednisolone, her platelet count increased to 108,000/mm3. With reference to this case, a brief review on refractory heparin-induced thrombocytopenia and the association of direct oral anticoagulants with thrombocytopenia is presented.
药物诱导的血小板减少症可能发生在住院患者中,并使其抗血栓治疗复杂化。几种药物可以将血小板减少症与免疫和非免疫机制联系起来。血小板减少症可在新药开始后数小时至数月内的任何时间发生。在这项研究中,我们描述了一名女性患者在使用非甾体抗炎药后出现急性或慢性肾损伤,出现导管相关血栓形成,并接受肝素治疗5天,没有任何并发症。她在5天后出院,并规定每天两次使用阿哌沙班2.5 mg。然而,她在24小时后因疲劳、瘀点和严重血小板减少症(7000/mm3)再次入院。由于血小板减少症的其他原因,检查结果为阴性。由于可能被诊断为与药物相关的血小板减少症,阿哌沙班被停用。静脉注射免疫球蛋白治疗后,她的血小板计数增加并稳定在40-50000/mm3左右。因此,通过调整剂量的利伐沙班(10-15mg/天)继续抗凝。阿哌沙班停药和泼尼松治疗17天后,她的血小板计数增加到108000/mm3。针对这一病例,简要回顾了难治性肝素诱导的血小板减少症以及直接口服抗凝剂与血小板减少症的关系。
{"title":"Severe and Prolonged Thrombocytopenia Following Heparin and Apixaban Use: A Case Report and Literature Review","authors":"Foroud Shahbazi, M. Salimi","doi":"10.2174/1574885519666230825153414","DOIUrl":"https://doi.org/10.2174/1574885519666230825153414","url":null,"abstract":"\u0000\u0000Drug-induced thrombocytopenia can occur in hospitalized patients and complicate their antithrombotic treatment. Several medications can associate thrombocytopenia with immune and non-immune mechanisms. Thrombocytopenia can occur at any time from a few hours to months after a new medication initiation. In this study, we have described the case of a female patient with acute-on-chronic kidney injury following a non-steroidal anti-inflammatory agent use, who developed catheter-related thrombosis and was treated with heparin without any complication for 5 days. She was discharged after 5 days and prescribed to use apixaban 2.5 mg twice daily. However, she was readmitted after 24 hours with fatigue, petechiae, and severe thrombocytopenia (7000/mm3). The workup was negative for other reasons of thrombocytopenia. With a possible diagnosis of drug-related thrombocytopenia, apixaban was discontinued. Following the treatment with the intravenous immunoglobulin, her platelet counts increased and stabilized around 40-50,000/mm3. Anticoagulation was thus continued with adjusted doses of rivaroxaban (10-15 mg/day). 17 days after apixaban discontinuation and treatment with prednisolone, her platelet count increased to 108,000/mm3. With reference to this case, a brief review on refractory heparin-induced thrombocytopenia and the association of direct oral anticoagulants with thrombocytopenia is presented.\u0000","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2023-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44809085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Drug Therapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1